Note 8 - Income Tax - Schedule of Deferred Tax Assets and Liabilities 1 (Details) - USD ($) $ in Thousands |
Dec. 31, 2023 |
Dec. 31, 2022 |
|---|---|---|
| Net operating loss carryforwards | $ 9,179 | $ 7,850 |
| Accrued expenses, tax assets | 406 | 364 |
| Capitalized R&D | 4,548 | 3,152 |
| Total deferred tax assets | 16,014 | 20,749 |
| Less: valuation allowance: | (16,014) | (20,749) |
| Net deferred tax asset | 0 | 0 |
| Pieris Pharmaceuticals, Inc. [Member] | ||
| Net operating loss carryforwards | 67,496 | 54,845 |
| Share-based awards compensation, tax assets | 2,624 | 3,112 |
| Accrued expenses, tax assets | 461 | 216 |
| R&D Credits | 644 | 413 |
| Depreciation and other | 479 | 384 |
| Unrealized foreign currency | (377) | 359 |
| Capitalized R&D | 1,165 | 952 |
| Lease liability | 0 | 3,541 |
| Total deferred tax assets | 72,492 | 63,822 |
| Right-of-use asset | 0 | (3,270) |
| Accrued expenses, tax liabilities | 0 | 0 |
| Total deferred tax liabilities | 0 | (3,270) |
| Less: valuation allowance: | (72,492) | (60,552) |
| Net deferred tax asset | $ 0 | $ 0 |
| X | ||||||||||
- Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liability No definition available.
|
| X | ||||||||||
- Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued compensation and other costs No definition available.
|
| X | ||||||||||
- Definition Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized research and development. No definition available.
|
| X | ||||||||||
- Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from depreciation and other expenses. No definition available.
|
| X | ||||||||||
- Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from unrealized losses (gains) on foreign currency transactions. No definition available.
|
| X | ||||||||||
- Definition Amount of deferred tax liability attributable to taxable temporary differences from lease right-of-use assets No definition available.
|
| X | ||||||||||
- Definition Amount of deferred tax liability attributable to taxable temporary differences. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of deferred tax liability attributable to taxable temporary differences from capitalized costs. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|